Comparative Pharmacology
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus SYNAREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus SYNAREL.
LUPRON DEPOT-PED KIT vs SYNAREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
Synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). Binds to pituitary GnRH receptors, initially stimulating then desensitizing them, leading to suppressed LH and FSH secretion, decreased gonadal steroid production (estrogen, testosterone).
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
200 mcg intranasally twice daily (400 mcg total daily dose) for 6 months. Initiate on day 5 of menstural cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Terminal elimination half-life: ~3 hours (range 2-5 hours) after intranasal administration; clinically, dosing every 12 hours maintains therapeutic levels.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Renal: ~90% as parent drug and metabolites; fecal: <10%.
Category C
Category C
GnRH Agonist
GnRH Agonist